Diabetes and metabolism Archives

Videos

Clinical case: Tirzepatide dose reduction and the impact on long-term maintenance of weight loss

In this Quick Case, Endocrinologist A/Prof Samantha Hocking outlines evidence from the SURMOUNT-MAINTAIN study, demonstrating how tirzepatide dose reduction or elimination impacts the maintenance of weight loss, cardiometabolic benefits, and clinical decision-making in obesity management (5 mins).

Videos

Tirzepatide KwikPen update: Practical guidance for clinicians

In this Product Explainer, A/Prof Samantha Hocking, Endocrinologist, explains the key changes to the tirzepatide KwikPen device, including operational steps, dosing considerations and patient counselling, with practical guidance for supporting safe and effective use (7 mins).

Podcasts

Practical guide to improving control of T2D

Professor Roger Chen provides an update on the latest recommendations for prescribing GLP-1 agonist in T2D.

Videos

An update on semaglutide for CKD in the presence of T2D

In this Product Explainer, Endocrinologist Prof Richard MacIsaac provides an update on the chronic kidney disease (CKD) indication for semaglutide, explains the PBS criteria and how healthcare professionals can initiate this GLP-1 RA.

Podcasts

The role of GLP-1 in the management of CKD in T2D

Dr Charlotte Hespe and Dr Ramy Bishay discuss the latest recommendations for screening and assessing patients for early stage CKD.

Clinical Articles

Fatty liver: an early warning sign of cardiovascular and cancer risk

Simple, non-invasive tests now allow GPs to identify those at risk earlier and intensify prevention…

Podcasts

Chronic kidney disease in diabetes: What clinicians need to check early – Panel

A practical, case-based panel i showing how kidney, cardiovascular and metabolic risks intersect in diabetes, and how current therapies can be combined for meaningful long term benefit.

Podcasts

From screening to action: Practical CKD tips for healthcare professionals – Panel

Hear about why urine ACR is critical, the hidden risks of CKD Stage 3A, and how new therapies like SGLT2 inhibitors and GLP-1 receptor agonists are changing care - even beyond diabetes.

Podcasts

SGLT2s and renal protection

Understand CKD screening priorities, risk mitigation strategies, and the role of SGLT-2 inhibitors in preventing progression and complications.

Podcasts

Panel discussion on GLP1s for chronic kidney disease in type 2 diabetes

Advice and evidence for and role of GLP-1 receptor agonists in the prevention and management of kidney disease in patients with type 2 diabetes will be discussed.

Videos

Management of a gluten free diet with GluteGuard

In this Product Explainer, Gastroenterologist Prof Finlay Macrae AO explains the common challenges when following a strict gluten free diet and the role of enzyme supplementation with GluteGuard.

Clinical Articles

Tirzepatide vs semaglutide: A head-to-head comparison for management of obesity

The SURMOUNT-5 trial has provided definitive evidence that tirzepatide is superior to semaglutide for obesity treatment, achieving an additional 6.5% body weight reduction and nearly doubling the proportion of patients who lose 25% or more of their body weight.

Diabetes and metabolism

Clinical case: Tirzepatide dose reduction and the impact on long-term maintenance of weight loss

In this Quick Case, Endocrinologist A/Prof Samantha Hocking outlines evidence from the SURMOUNT-MAINTAIN study, demonstrating how tirzepatide dose reduction or elimination impacts the maintenance of weight loss, cardiometabolic benefits, and clinical decision-making in obesity management (5 mins).

Tirzepatide KwikPen update: Practical guidance for clinicians

In this Product Explainer, A/Prof Samantha Hocking, Endocrinologist, explains the key changes to the tirzepatide KwikPen device, including operational steps, dosing considerations and patient counselling, with practical guidance for supporting safe and effective use (7 mins).

Practical guide to improving control of T2D

Professor Roger Chen provides an update on the latest recommendations for prescribing GLP-1 agonist in T2D.

An update on semaglutide for CKD in the presence of T2D

In this Product Explainer, Endocrinologist Prof Richard MacIsaac provides an update on the chronic kidney disease (CKD) indication for semaglutide, explains the PBS criteria and how healthcare professionals can initiate this GLP-1 RA.

The role of GLP-1 in the management of CKD in T2D

Dr Charlotte Hespe and Dr Ramy Bishay discuss the latest recommendations for screening and assessing patients for early stage CKD.

Fatty liver: an early warning sign of cardiovascular and cancer risk

Simple, non-invasive tests now allow GPs to identify those at risk earlier and intensify prevention…

Chronic kidney disease in diabetes: What clinicians need to check early – Panel

A practical, case-based panel i showing how kidney, cardiovascular and metabolic risks intersect in diabetes, and how current therapies can be combined for meaningful long term benefit.

From screening to action: Practical CKD tips for healthcare professionals – Panel

Hear about why urine ACR is critical, the hidden risks of CKD Stage 3A, and how new therapies like SGLT2 inhibitors and GLP-1 receptor agonists are changing care - even beyond diabetes.

SGLT2s and renal protection

Understand CKD screening priorities, risk mitigation strategies, and the role of SGLT-2 inhibitors in preventing progression and complications.

Panel discussion on GLP1s for chronic kidney disease in type 2 diabetes

Advice and evidence for and role of GLP-1 receptor agonists in the prevention and management of kidney disease in patients with type 2 diabetes will be discussed.

Management of a gluten free diet with GluteGuard

In this Product Explainer, Gastroenterologist Prof Finlay Macrae AO explains the common challenges when following a strict gluten free diet and the role of enzyme supplementation with GluteGuard.

Tirzepatide vs semaglutide: A head-to-head comparison for management of obesity

The SURMOUNT-5 trial has provided definitive evidence that tirzepatide is superior to semaglutide for obesity treatment, achieving an additional 6.5% body weight reduction and nearly doubling the proportion of patients who lose 25% or more of their body weight.

Get the app

Site

Company

Connect

Legal

Healthed

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.

Diabetes and metabolism

In this Quick Case, Endocrinologist A/Prof Samantha Hocking outlines evidence from the SURMOUNT-MAINTAIN study, demonstrating how tirzepatide dose reduction or elimination impacts the maintenance of weight loss, cardiometabolic benefits, and clinical decision-making in obesity management (5 mins).

In this Product Explainer, A/Prof Samantha Hocking, Endocrinologist, explains the key changes to the tirzepatide KwikPen device, including operational steps, dosing considerations and patient counselling, with practical guidance for supporting safe and effective use (7 mins).

Professor Roger Chen provides an update on the latest recommendations for prescribing GLP-1 agonist in T2D.

In this Product Explainer, Endocrinologist Prof Richard MacIsaac provides an update on the chronic kidney disease (CKD) indication for semaglutide, explains the PBS criteria and how healthcare professionals can initiate this GLP-1 RA.

Dr Charlotte Hespe and Dr Ramy Bishay discuss the latest recommendations for screening and assessing patients for early stage CKD.

Simple, non-invasive tests now allow GPs to identify those at risk earlier and intensify prevention…

A practical, case-based panel i showing how kidney, cardiovascular and metabolic risks intersect in diabetes, and how current therapies can be combined for meaningful long term benefit.

Hear about why urine ACR is critical, the hidden risks of CKD Stage 3A, and how new therapies like SGLT2 inhibitors and GLP-1 receptor agonists are changing care - even beyond diabetes.

Understand CKD screening priorities, risk mitigation strategies, and the role of SGLT-2 inhibitors in preventing progression and complications.

Advice and evidence for and role of GLP-1 receptor agonists in the prevention and management of kidney disease in patients with type 2 diabetes will be discussed.

In this Product Explainer, Gastroenterologist Prof Finlay Macrae AO explains the common challenges when following a strict gluten free diet and the role of enzyme supplementation with GluteGuard.

The SURMOUNT-5 trial has provided definitive evidence that tirzepatide is superior to semaglutide for obesity treatment, achieving an additional 6.5% body weight reduction and nearly doubling the proportion of patients who lose 25% or more of their body weight.

Save time on registrations, track CPD, listen to full podcasts... sign in to your Healthed account now

Don't have an existing account? Sign up today

Extra Details

Healthed

Upcoming Healthed Webcast

New Brain Health Guidelines – What GPs Can Do

Tuesday 4th August, 7pm - 9pm AEST

Speaker

Scientia Prof Kaarin Anstey

Psychologist; Director, UNSW Ageing Futures Institute; ARC Laureate Fellow; Senior Principal Research Scientist, NeuRA

Scientia Prof Kaarin Anstey translates the WHO's updated 2026 dementia risk-reduction guidelines changes into concrete actions for opportunistic risk assessment and targeted advice in everyday general practice.